サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1436627

サイケデリックドラッグの世界市場レポート2024

Psychedelic Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
サイケデリックドラッグの世界市場レポート2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

サイケデリックドラッグの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には16.1%の年間複合成長率（CAGR）で102億米ドルに成長すると予想されます。予測期間中に予想される成長は、医薬品開発の進歩、治療用途の拡大、医療界での受け入れの拡大、公共政策の変化、メンタルヘルス危機への対応に起因すると考えられます。予測期間中に予想される主な動向には、教育と国民の意識、法規制の発展、サイケデリック化合物の多様化、患者中心の治療アプローチの採用への焦点が含まれます。

精神疾患の急増により、今後サイケデリックドラッグ市場の拡大が見込まれます。精神疾患には、苦痛や心的外傷後ストレス障害など、感情、思考、行動の変化を特徴とする健康状態が含まれます。 サイケデリックドラッグはうつ病や心的外傷後ストレス障害の治療に有効であることが実証されており、定期的な使用により精神疾患の軽減に貢献しています。たとえば、2022年 11月に英国に本拠を置く国立社会研究センターが報告したように、精神障害の疑いのある17～19歳の割合は、2021年の17.4%から2022年の25.7%に増加しました。精神疾患の症例数の増加は、サイケデリックドラッグ市場の成長の大きな原動力となっています。

メンタルヘルスに関連する政府の取り組みやプログラムは、サイケデリックドラッグ市場をさらに推進する態勢が整っています。政府の取り組みには、特定の問題への取り組み、目標の達成、または国民のニーズへの対応を目的として政府が実行する計画された行動、プロジェクト、またはプログラムが含まれます。これらの取り組みは調査と臨床試験を促進し、サイケデリック物質の治療の可能性と安全性プロファイルの理解を進めます。さらに、政府主導による医療用途の規制改革や承認により、サイケデリックな治療法の開発と商業化にとってより有利な環境が生まれています。たとえば、2022年 2月、米国に本拠を置く金融およびビジネスニュースウェブサイト Business Insiderが報じたように、チリは2021年にメンタルヘルス予算を300%以上増加すると発表し、カナダは2021年にメンタルヘルスに10億米ドルの基金を割り当てました。 2021年の予算です。したがって、政府の取り組みとメンタルヘルスプログラムは、サイケデリックドラッグ市場の成長に大きく貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のサイケデリックドラッグ市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • リゼルグ酸ジエチルアミド（LSD）
  • ケタミン
  • フェンシクリジン
  • ガンマヒドロキシ酪酸（GHB）
  • サルビア
  • 世界のサイケデリックドラッグ市場、疾患適応別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • うつ
  • PTSD
  • 世界のサイケデリックドラッグ市場、由来別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 天然
  • 合成
  • 世界のサイケデリックドラッグ市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 治療抵抗性のうつ病
  • アヘン中毒
  • 心的外傷後ストレス障害
  • ナルコレプシー
  • パニック障害
  • 世界のサイケデリックドラッグ市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域および国の分析

  • 世界のサイケデリックドラッグ市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のサイケデリックドラッグ市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • サイケデリックドラッグ市場の競合情勢
  • サイケデリックドラッグ市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson
    • Merck &Co. Inc.
    • AbbVie Inc.
    • Novartis International AG

第31章 その他の主要および革新的な企業

  • AstraZeneca PLC
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited
  • Mylan NV
  • Jazz Pharmaceuticals plc
  • Dr. Reddy's Laboratories Ltd
  • Hikma Pharmaceuticals PLC
  • Mydecine Innovations Group Inc.
  • Cybin Inc.
  • Silo Wellness Inc.
  • Emmes Company
  • Celon Pharma SA
  • Klarisana
  • Mota Ventures Corp.
  • BetterLife Pharma Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r15961

Psychedelic drugs constitute a category of psychoactive substances that induce alterations in perception, mood, and thought processes. These substances impact all senses, leading to changes in an individual's thinking, perception of time, and emotions. Examples include chemicals such as Lysergic acid diethylamide (LSD) and plants such as peyote. Psychedelic drugs find applications in the treatment of various mental health conditions.

Psychedelic drugs come in different types, including lysergic acid diethylamide (LSD), ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. LSD, colloquially known as acid, is manufactured in crystalline form and diluted for ingestion. These drugs are used for various disease indications such as depression and PTSD, with applications in treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

The psychedelic drugs market research report is one of a series of new reports from The Business Research Company that provides psychedelic drugs market statistics, including psychedelic drugs industry global market size, regional shares, competitors with a psychedelic drugs market share, detailed psychedelic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. This psychedelic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The psychedelic drugs market size has grown rapidly in recent years. It will grow from $4.88 billion in 2023 to $5.62 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth observed in the historic period can be attributed to factors such as a shifting regulatory landscape, heightened awareness regarding mental health, and changing public perception.

The psychedelic drugs market size is expected to see rapid growth in the next few years. It will grow to $10.2 billion in 2028 at a compound annual growth rate (CAGR) of 16.1%. The expected growth in the forecast period can be attributed to advancements in drug development, the expansion of therapeutic applications, growing acceptance in the medical community, public policy shifts, and the response to the mental health crisis. Key trends anticipated in the forecast period include a focus on education and public awareness, legal and regulatory developments, diversification of psychedelic compounds, and the adoption of patient-centric treatment approaches.

The surge in cases of mental illnesses is anticipated to drive the expansion of the psychedelic drugs market in the future. Mental illnesses encompass health conditions characterized by alterations in emotion, thinking, or behavior, including distress and post-traumatic stress disorder. Psychedelic drugs have demonstrated effectiveness in treating depression and post-traumatic stress disorder, contributing to the reduction of mental illnesses through regular use. For instance, in November 2022, as reported by the UK-based National Centre for Social Research, the percentage of 17- to 19-year-olds with a suspected mental disorder increased from 17.4% in 2021 to 25.7% in 2022. Consequently, the rising number of mental illness cases is a significant driver behind the growth of the psychedelic drugs market.

Government initiatives and programs related to mental health are poised to further propel the psychedelic drugs market. Government initiatives encompass planned actions, projects, or programs executed by a government to address specific issues, achieve goals, or respond to public needs. These initiatives facilitate research and clinical trials, advancing the understanding of the therapeutic potential and safety profiles of psychedelic substances. Furthermore, regulatory reforms or approvals for medical use, driven by government initiatives, create a more conducive environment for the development and commercialization of psychedelic-based treatments. For example, in February 2022, as reported by Business Insider, the US-based financial and business news website, Chile announced a more than 300% increase in the mental health budget in 2021, and Canada allocated a $1 billion fund for mental health in its 2021 Budget. Hence, government initiatives and mental health programs are significant contributors to the growth of the psychedelic drugs market.

The prevailing trend in the psychedelic drug market is the introduction of depression spray, with major companies taking steps to sustain their positions by offering nasal spray drugs for major depressive disorders. For example, in August 2021, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched KLOXXADO, an 8 mg nasal spray containing naloxone HCl. This nasal spray is designed for the immediate care of patients, both adults and children, experiencing known or suspected opioid overdoses, as indicated by respiratory depression and/or central nervous system depression.

A notable strategy among major companies in the psychedelic drugs market involves forming partnerships to develop new products and strengthen market positions. Collaborations and partnerships in this sector facilitate the sharing of expertise, resources, and research efforts, expediting the development of innovative treatments and enhancing the understanding of the therapeutic potential of psychedelics. For instance, in March 2022, SciSparc Ltd., an Israel-based biopharmaceutical company, collaborated with Clearmind Medicine Inc., a Canada-based pharmaceutical company. The partnership focuses on exploring the development of innovative compounds in the psychedelic field, aiming to create drug candidates with robust efficacy and safety profiles for treating mental health-related diseases. The collaboration includes joint pre-clinical studies, and both companies anticipate that positive results could deepen their partnership in the pursuit of novel psychedelic-derived therapeutics. This strategic alliance reflects the growing interest and investment in the psychedelic pharmaceutical sector, driven by the potential for groundbreaking treatments and addressing underserved health problems.

In April 2022, Numinus, a Canada-based company specializing in psychedelic medicine with integrated psychotherapy, acquired Novamind for $20.77 million. This acquisition positions Numinus to expand its psychotherapy clinics in the US and advance psychedelic programs. Novamind, a US-based mental health company and psychedelic medicine manufacturer, contributes to Numinus's strategic growth in the evolving landscape of psychedelic treatments.

Major companies operating in the psychedelic drugs market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Roche Holding AG, Takeda Pharmaceutical Company Limited, Mylan N.V., Jazz Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Mydecine Innovations Group Inc., Cybin Inc., Silo Wellness Inc., Emmes Company, Celon Pharma S.A., Klarisana, Mota Ventures Corp., BetterLife Pharma Inc., MindMed Inc., Numinus Wellness Inc., Revive Therapeutics Ltd., Field Trip Health Ltd., Red Light Holland Corp., Avadel Pharmaceuticals PLC, PsyBio Therapeutics Corp., Eleusian Biosciences Corp., Seelos Therapeutics Inc., COMPASS Pathways PLC, NeuroRx Inc.

North America was the largest region in the psychedelic drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the psychedelic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The psychedelic drugs market consists of sales of psilocybin, PCP, cannabis, and ecstasy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Psychedelic Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on psychedelic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for psychedelic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The psychedelic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Lysergic Acid Diethylamide (LSD); Ketamine; Phencyclidine; Gamma Hydroxybutyric Acid (GHB); Salvia
  • 2) By Disease Indication: Depression; PTSD
  • 3) By Origin: Natural; Synthetic
  • 4) By Application: Treatment-Resistant Depression; Opiate addiction; Post- Traumatic Stress Disorder; Narcolepsy; Panic Disorders
  • 5) By Distribution Channel: Hospitals Pharmacy; Retail Pharmacy; Online Pharmacy
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Novartis International AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Psychedelic Drugs Market Characteristics

3. Psychedelic Drugs Market Trends And Strategies

4. Psychedelic Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Psychedelic Drugs Market Size and Growth

  • 5.1. Global Psychedelic Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Psychedelic Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Psychedelic Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Psychedelic Drugs Market Segmentation

  • 6.1. Global Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lysergic Acid Diethylamid (LSD)
  • Ketamine
  • Phencyclidine
  • Gamma Hydroxybutyric Acid (GHB)
  • Salvia
  • 6.2. Global Psychedelic Drugs Market, Segmentation By disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Depression
  • PTSD
  • 6.3. Global Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Natural
  • Synthetic
  • 6.4. Global Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Treatment-Resistant Depression
  • Opiate addiction
  • Post- Traumatic Stress Disorder
  • Narcolepsy
  • Panic Disorders
  • 6.5. Global Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

7. Psychedelic Drugs Market Regional And Country Analysis

  • 7.1. Global Psychedelic Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Psychedelic Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Psychedelic Drugs Market

  • 8.1. Asia-Pacific Psychedelic Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Psychedelic Drugs Market

  • 9.1. China Psychedelic Drugs Market Overview
  • 9.2. China Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Psychedelic Drugs Market

  • 10.1. India Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Psychedelic Drugs Market

  • 11.1. Japan Psychedelic Drugs Market Overview
  • 11.2. Japan Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Psychedelic Drugs Market

  • 12.1. Australia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Psychedelic Drugs Market

  • 13.1. Indonesia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Psychedelic Drugs Market

  • 14.1. South Korea Psychedelic Drugs Market Overview
  • 14.2. South Korea Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Psychedelic Drugs Market

  • 15.1. Western Europe Psychedelic Drugs Market Overview
  • 15.2. Western Europe Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Psychedelic Drugs Market

  • 16.1. UK Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Psychedelic Drugs Market

  • 17.1. Germany Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Psychedelic Drugs Market

  • 18.1. France Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Psychedelic Drugs Market

  • 19.1. Italy Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Psychedelic Drugs Market

  • 20.1. Spain Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Psychedelic Drugs Market

  • 21.1. Eastern Europe Psychedelic Drugs Market Overview
  • 21.2. Eastern Europe Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Psychedelic Drugs Market

  • 22.1. Russia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Psychedelic Drugs Market

  • 23.1. North America Psychedelic Drugs Market Overview
  • 23.2. North America Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Psychedelic Drugs Market

  • 24.1. USA Psychedelic Drugs Market Overview
  • 24.2. USA Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Psychedelic Drugs Market

  • 25.1. Canada Psychedelic Drugs Market Overview
  • 25.2. Canada Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Psychedelic Drugs Market

  • 26.1. South America Psychedelic Drugs Market Overview
  • 26.2. South America Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Psychedelic Drugs Market

  • 27.1. Brazil Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Psychedelic Drugs Market

  • 28.1. Middle East Psychedelic Drugs Market Overview
  • 28.2. Middle East Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Psychedelic Drugs Market

  • 29.1. Africa Psychedelic Drugs Market Overview
  • 29.2. Africa Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Psychedelic Drugs Market, Segmentation By Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Psychedelic Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Psychedelic Drugs Market Competitive Landscape
  • 30.2. Psychedelic Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis International AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Psychedelic Drugs Market Other Major And Innovative Companies

  • 31.1. AstraZeneca PLC
  • 31.2. Roche Holding AG
  • 31.3. Takeda Pharmaceutical Company Limited
  • 31.4. Mylan N.V.
  • 31.5. Jazz Pharmaceuticals plc
  • 31.6. Dr. Reddy's Laboratories Ltd
  • 31.7. Hikma Pharmaceuticals PLC
  • 31.8. Mydecine Innovations Group Inc.
  • 31.9. Cybin Inc.
  • 31.10. Silo Wellness Inc.
  • 31.11. Emmes Company
  • 31.12. Celon Pharma S.A.
  • 31.13. Klarisana
  • 31.14. Mota Ventures Corp.
  • 31.15. BetterLife Pharma Inc.

32. Global Psychedelic Drugs Market Competitive Benchmarking

33. Global Psychedelic Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Psychedelic Drugs Market

35. Psychedelic Drugs Market Future Outlook and Potential Analysis

  • 35.1 Psychedelic Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Psychedelic Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Psychedelic Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer